Breaking News, Collaborations & Alliances

Catalent Signs Commercial Mfg. Agreement with US WorldMeds

Will manufacture lofexidine, an investigational drug under development to mitigate symptoms associated with opioid withdrawal

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Catalent Pharma Solutions has entered into an exclusive agreement with US WorldMeds, LLC for the commercial manufacture of lofexidine, an investigational drug under development to mitigate symptoms associated with opioid withdrawal and facilitate completion of opioid discontinuation treatment. US WorldMeds has the rights to commercialize lofexidine in the U.S., which is currently approved as Britlofex in the UK. Catalent and US WorldMeds have worked together to successfully tech transfer the ...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters